New
Attralus
The AI engine Fit Assessment
BetaAttralus develops immunotherapies and diagnostic tools to treat systemic amyloid diseases, aiming to efficiently clear amyloid fibrils and improve patient outcomes.
Blurb
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.
HQ Location
San Francisco (United States)
Founded
2019
Employees
31
Total funding raised
$197.00M
Last Funding Event
Series B, $56.00M, February 6, 2024
Smart insights
- 6m headcount growth: 6%
- 1Y headcount growth: 24%
- Headcount-to-last-round ratio: 1.2 employees/$M
Developer of immunotherapies and an imaging diagnostic platform designed for multiple systemic amyloid disease treatments. The company specializes in developing immunotherapies to clear amyloid fibrils in patients with systemic amyloid diseases, like a light chain, transthyretin, and LECT2 amyloidosis, enabling the healthcare industry to treat amyloidosis patients efficiently.